Skip to Main Content

++

INTRODUCTION

++

tioconazole (tye-oh-kon-a-zole)

1-Day, Monistat-1 Day, Vagistat-1

Classification

Therapeutic: antifungals (vaginal)

Pharmacologic: imidazoles

++
Indications
++

Treatment of vulvovaginal candidiasis.

++
Action
++

Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Not active against bacteria. Therapeutic Effects: Inhibited growth and death of susceptible Candida, with ↓ in accompanying symptoms of vulvovaginitis (vaginal burning, itching, discharge).

++
Adverse Reactions/Side Effects
++

GU: irritation, vulvovaginal burning.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor patient's symptoms to help document drug effectiveness.

++
Interventions
++

  • Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection.

++
Patient/Client-Related Instruction
++

  • Advise patient to report any increased local sensitivity to this drug (pain, burning, itching, swelling).

  • Therapeutic response for vaginal infections is usually seen after 1 wk. Advise patient that application is typically continued throughout the full course of therapy even if feeling better. Therapy should be continued during menstrual period.

  • Advise patient to seek medical help if infections persist or recur after the full treatment. Recurrent fungal infections may be a sign of systemic illness.

++
Pharmacokinetics
++

Absorption: Minimal through intact skin.

++

Distribution: Unknown. Action is primarily local.

++

Metabolism and Excretion: Negligible with local application.

++

Half-life: Not applicable.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
intravaginal unknown unknown unknown

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity to active ingredients, additives, or preservatives; OB/Lactation: Safety not established.

++

Use Cautiously in: Patients with recurrent vulvovaginal yeast infections.

++
Interactions
++

Drug-Drug: Not known.

++
Route/Dosage
++

Vag (Adults and Children ≥12 yr): Vaginal ointment—1 applicatorful (4.6 g) hs as a single dose.

++
Availability
++

Vaginal ointment: 6.5% OTC.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.